药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Tiludronic acid
Nivolumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Nivolumab.
Tiludronic acid
Vedolizumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Vedolizumab.
Tiludronic acid
Secukinumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Secukinumab.
Tiludronic acid
Obinutuzumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Obinutuzumab.
Tiludronic acid
Certolizumab pegol
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Certolizumab pegol.
Tiludronic acid
Raxibacumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Raxibacumab.
Tiludronic acid
Belimumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Belimumab.
Tiludronic acid
Golimumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Golimumab.
Tiludronic acid
Ofatumumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Ofatumumab.
Tiludronic acid
Volociximab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Volociximab.
Tiludronic acid
Denosumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Denosumab.
Tiludronic acid
Mepolizumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Mepolizumab.
Tiludronic acid
Catumaxomab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Catumaxomab.
Tiludronic acid
Teplizumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Teplizumab.
Tiludronic acid
Reslizumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Reslizumab.
Tiludronic acid
Lexatumumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Lexatumumab.
Tiludronic acid
Lerdelimumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Lerdelimumab.
Tiludronic acid
Bivatuzumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Bivatuzumab.
Tiludronic acid
Sibrotuzumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Sibrotuzumab.
Tiludronic acid
Apolizumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Apolizumab.